Standard Contracts
EX-10.28(B) 50 d245388dex1028b.htm EX-10.28(B)Standard Exclusive License Agreement With Sublicensing Terms • May 5th, 2020
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
EX-10.11 8 agtc-ex1011_1071.htm EX-10.11 OMNIBUS AMENDMENT TO STANDARD EXCLUSIVE LICENSE AGREEMENT WITH SUBLICENSING TERMS (A3288) AND [***] AGREEMENTStandard Exclusive License Agreement With Sublicensing Terms • May 5th, 2020 • Florida
This OMNIBUS AMENDMENT TO STANDARD EXCLUSIVE LICENSE AGREEMENT WITH SUBLICENSING TERMS (A3288) AND [***] AGREEMENT (this “Amendment”) is made and entered into this 1st day of July, 2015 (the “Amendment Effective Date”) by and among University of Florida Research Foundation, Inc. (“UFRF”), a nonstock, nonprofit Florida corporation, the University of Florida Board of Trustees, a nonstock, nonprofit Florida corporation (“University”), Johns Hopkins University (“JHU”), a Maryland corporation and Applied Genetic Technologies Corporation, a Delaware corporation having a principal place of business at 11801 Research Drive, Suite D, Alachua, Florida 32615 (the “Licensee”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Joint Agreement (defined below) or the [***] (defined below) as applicable.
ContractStandard Exclusive License Agreement With Sublicensing Terms • February 13th, 2015 • Viewray Inc • Electromedical & electrotherapeutic apparatus
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
SECOND AMENDMENT To STANDARD EXCLUSIVE LICENSE AGREEMENT WITH SUBLICENSING TERMS (A3288)Standard Exclusive License Agreement With Sublicensing Terms • November 4th, 2013 • Applied Genetic Technologies Corp • Biological products, (no disgnostic substances)
This Second Amendment to the Standard Exclusive License Agreement With Sublicensing Terms (also known as Agreement A3288), dated October 7, 2003 and amended as of November 2004 (the “License Agreement”) is made as of this 25th day February, 2009 by and among Applied Genetic Technologies Corporation, a Delaware corporation (“AGTC”), the University of Florida Research Foundation, Inc., a non-stock, non-profit Florida corporation (“UFRF”) and Johns Hopkins University, a Maryland corporation (“JHU”).
FOURTH AMENDMENT TO STANDARD EXCLUSIVE LICENSE AGREEMENT WITH SUBLICENSING TERMSStandard Exclusive License Agreement With Sublicensing Terms • March 4th, 2014 • Applied Genetic Technologies Corp • Biological products, (no disgnostic substances)
This Fourth Amendment to the Standard Exclusive License Agreement With Sublicensing Terms (also known as Agreement A3288), dated October 7, 2003, amended as of November 2004 by First Amendment to the Standard Exclusive License Agreement with Sublicensing Terms, amended as of December 3, 2004 by AGTC Side Letter Amendments and Clarifications of License Agreements, amended as of February 25th 2009 by Second Amendment to the Standard Exclusive License Agreement With Sublicensing Terms and amended as of March 30, 2010 by AGTC Letter Agreement Third Amendment and Clarifications of JHU/UFRF License Agreement (the “License Agreement”) is made as of this 17th day of December, 2013 by and among Applied Genetic Technologies Corporation, a Delaware corporation (“AGTC”), the University of Florida Research Foundation, Inc., a non-stock, non-profit Florida corporation (“UFRF”) and Johns Hopkins University, a Maryland corporation (“JHU”).
